Results 21 to 30 of about 149,141 (380)

Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes [PDF]

, 2018
Objectives: Our objective was to evaluate factors associated with recurrence in patients with 027+ and 027– Clostridium difficile infection (CDI). Methods: Patients with CDI observed between January and December 2014 in six hospitals were consecutively ...
Aceti, A., Andreoni, M., Antonelli, G., Carfagna, P., Cauda, R., Delle Rose, D., Falcone, M., Fantoni, M., Farcomeni, A., Fontana, C., Goldoni, P., Iraci, F., Mastroianni, C., Murri, R., Petrosillo, N., Raponi, G., Sanguinetti, M., Santino, I., Tiseo, G., Venditti, M.   +19 more
core   +1 more source

Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms.

Journal of Antimicrobial Chemotherapy, 2018
Metronidazole, a nitroimidazole, remains a front-line choice for treatment of infections related to inflammatory disorders of the gastrointestinal tract including colitis linked to Clostridium difficile.
Simon A. Dingsdag, N. Hunter
semanticscholar   +1 more source

Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility.

PLoS ONE, 2020
Clostridioides difficile is responsible for various intestinal symptoms from mild diarrhea to severe pseudomembranous colitis and is the primary cause of antibiotic-associated diarrhea in adults.
Tri-Hanh-Dung Doan, Stéphanie Yen-Nicolaÿ, Marie-Françoise Bernet-Camard, Isabelle Martin-Verstraete, Séverine Péchiné   +4 more
doaj   +1 more source

Predictors of Failure from Primary Therapy for Giardiasis in San Diego: A Single Institution Retrospective Review. [PDF]

, 2019
This study aimed to determine the presence of giardiasis among HIV patients in San Diego, the rate of failure of metronidazole treatment, and factors associated with treatment failure.
Debnath, Anjan, Morris, Sheldon R, Reed, Sharon L   +2 more
core   +1 more source

Metronidazole-induced encephalopathy in a patient with pyogenic spondylitis: a case report

BMC Musculoskeletal Disorders, 2018
Background Metronidazole is an antimicrobial agent commonly used in the treatment of several protozoal and anaerobic infections. Neurotoxicity associated with metronidazole has been rarely reported, and the incidence of metronidazole-induced ...
Kazutaka Mizuta, Motoki Sonohata, Osamu Nozaki, Tomoki Kobatake, Daisuke Nakayama, Tadatsugu Morimoto, Masaaki Mawatari   +6 more
doaj   +1 more source

Metronidazole resistance: a hidden epidemic? [PDF]

, 2018
This is a personal reflection from working as a clinical microbiologist and becoming increasingly concerned over gaps in our knowledge of metronidazole resistance and its impact on clinical ...
Smith, Andrew
core   +1 more source

Review article: the global emergence of Helicobacter pylori antibiotic resistance. [PDF]

, 2016
BackgroundHelicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma.AimTo review recent trends in H.
Aramin, H, Crowe, SE, Gupta, S, Park, JY, Thung, I, Valasek, MA, Vavinskaya, V   +6 more
core   +1 more source

Antiamoebic Properties of the Actinomycete Metabolites Echinomycin A and Tirandamycin A [PDF]

, 2012
Entamoeba histolytica infects 50 million people per year, causing 100,000 deaths worldwide. The primary treatment for amoebiasis is metronidazole. However, increased pathogen resistance combined with the drug’s toxic side effects encourages a search for ...
Espinosa, Avelina, Rowley, David C., Ryke, Erica, Socha, Aaron M.   +3 more
core   +3 more sources

Metronidazole-associated Neurologic Events: A Nested-Case Control Study.

Clinical Infectious Diseases, 2020
BACKGROUND Case reports have described instances of peripheral and central nervous system toxicity during treatment with metronidazole, however, no large-scale studies have examined this association.
N. Daneman, Yi Cheng, T. Gomes, J. Guan, M. Mamdani, F. Saxena, D. Juurlink   +6 more
semanticscholar   +1 more source

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

Clinical Infectious Diseases, 2016
In this randomized phase 3 trial, ceftazidime-avibactam plus metronidazole was noninferior to meropenem in treating complicated intra-abdominal infection, with similar efficacy against ceftazidime-resistant and ceftazidime-susceptible pathogens and no ...
J. Mazuski, L. Gasink, J. Armstrong, H. Broadhurst, G. Stone, Douglas R. Rank, L. Llorens, P. Newell, J. Pachl   +8 more
semanticscholar   +1 more source